Research ExplorerPublicationsPatterns of Clinical Progression in Radiorecurrent High-risk...

Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer

Standard

Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. / Philipson, Rebecca G; Romero, Tahmineh; Wong, Jessica K; Stish, Bradley J; Dess, Robert T; Spratt, Daniel E; Pilar, Avinash; Reddy, Chandana; Wedde, Trude B; Lilleby, Wolfgang A; Fiano, Ryan; Merrick, Gregory S; Stock, Richard G; Demanes, D Jeffrey; Moran, Brian J; Braccioforte, Michelle; Tran, Phuoc T; Martin, Santiago; Martinez-Monge, Rafael; Krauss, Daniel J; Abu-Isa, Eyad I; Valle, Luca; Chong, Natalie; Pisansky, Thomas M; Choo, C Richard; Song, Daniel Y; Greco, Stephen; Deville, Curtiland; McNutt, Todd; DeWeese, Theodore L; Ross, Ashley E; Ciezki, Jay P; Tilki, Derya; Karnes, R Jeffrey; Klein, Eric A; Tosoian, Jeffrey J; Boutros, Paul C; Nickols, Nicholas G; Bhat, Prashant; Shabsovich, David; Juarez, Jesus E; Kupelian, Patrick A; Rettig, Matthew B; Berlin, Alejandro; Tward, Jonathan D; Davis, Brian J; Reiter, Robert E; Steinberg, Michael L; Elashoff, David; Horwitz, Eric M; Tendulkar, Rahul D; Kishan, Amar U.

In: EUR UROL, Vol. 80, No. 2, 08.2021, p. 142-146.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Philipson, RG, Romero, T, Wong, JK, Stish, BJ, Dess, RT, Spratt, DE, Pilar, A, Reddy, C, Wedde, TB, Lilleby, WA, Fiano, R, Merrick, GS, Stock, RG, Demanes, DJ, Moran, BJ, Braccioforte, M, Tran, PT, Martin, S, Martinez-Monge, R, Krauss, DJ, Abu-Isa, EI, Valle, L, Chong, N, Pisansky, TM, Choo, CR, Song, DY, Greco, S, Deville, C, McNutt, T, DeWeese, TL, Ross, AE, Ciezki, JP, Tilki, D, Karnes, RJ, Klein, EA, Tosoian, JJ, Boutros, PC, Nickols, NG, Bhat, P, Shabsovich, D, Juarez, JE, Kupelian, PA, Rettig, MB, Berlin, A, Tward, JD, Davis, BJ, Reiter, RE, Steinberg, ML, Elashoff, D, Horwitz, EM, Tendulkar, RD & Kishan, AU 2021, 'Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer', EUR UROL, vol. 80, no. 2, pp. 142-146. https://doi.org/10.1016/j.eururo.2021.04.035

APA

Philipson, R. G., Romero, T., Wong, J. K., Stish, B. J., Dess, R. T., Spratt, D. E., Pilar, A., Reddy, C., Wedde, T. B., Lilleby, W. A., Fiano, R., Merrick, G. S., Stock, R. G., Demanes, D. J., Moran, B. J., Braccioforte, M., Tran, P. T., Martin, S., Martinez-Monge, R., ... Kishan, A. U. (2021). Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. EUR UROL, 80(2), 142-146. https://doi.org/10.1016/j.eururo.2021.04.035

Vancouver

Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE et al. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. EUR UROL. 2021 Aug;80(2):142-146. https://doi.org/10.1016/j.eururo.2021.04.035

Bibtex

@article{23edcfcd8366486987590f9fbbcb5757,
title = "Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer",
abstract = "The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously received either external beam radiation therapy (EBRT, n = 654, 67%) or EBRT + brachytherapy (EBRT + BT, n = 324, 33%) across 15 institutions from 1997 to 2015. In men who did not die, median follow-up after treatment was 8.9 yr and median follow-up after biochemical recurrence (BCR) was 3.7 yr. Local and systemic therapy salvage, respectively, were delivered to 21 and 390 men after EBRT, and eight and 103 men after EBRT + BT. Overall, 435 men developed DM, and 248 were detected within 1 yr of BCR. Measured from time of recurrence, 5-yr DM rates were 50% and 34% after EBRT and EBRT + BT, respectively. Measured from BCR, 5-yr PCSM rates were 27% and 29%, respectively. Interval to BCR was independently associated with DM (p < 0.001) and PCSM (p < 0.001). These data suggest that radiorecurrent HRPCa has an aggressive natural history and that DM is clinically evident early after BCR. These findings underscore the importance of further investigations into upfront risk assessment and prompt systemic evaluation upon recurrence in HRPCa. PATIENT SUMMARY: High-risk prostate cancer that recurs after radiation therapy is an aggressive disease entity and spreads to other parts of the body (metastases). Some 60% of metastases occur within 1 yr. Approximately 30% of these patients die from their prostate cancer.",
author = "Philipson, {Rebecca G} and Tahmineh Romero and Wong, {Jessica K} and Stish, {Bradley J} and Dess, {Robert T} and Spratt, {Daniel E} and Avinash Pilar and Chandana Reddy and Wedde, {Trude B} and Lilleby, {Wolfgang A} and Ryan Fiano and Merrick, {Gregory S} and Stock, {Richard G} and Demanes, {D Jeffrey} and Moran, {Brian J} and Michelle Braccioforte and Tran, {Phuoc T} and Santiago Martin and Rafael Martinez-Monge and Krauss, {Daniel J} and Abu-Isa, {Eyad I} and Luca Valle and Natalie Chong and Pisansky, {Thomas M} and Choo, {C Richard} and Song, {Daniel Y} and Stephen Greco and Curtiland Deville and Todd McNutt and DeWeese, {Theodore L} and Ross, {Ashley E} and Ciezki, {Jay P} and Derya Tilki and Karnes, {R Jeffrey} and Klein, {Eric A} and Tosoian, {Jeffrey J} and Boutros, {Paul C} and Nickols, {Nicholas G} and Prashant Bhat and David Shabsovich and Juarez, {Jesus E} and Kupelian, {Patrick A} and Rettig, {Matthew B} and Alejandro Berlin and Tward, {Jonathan D} and Davis, {Brian J} and Reiter, {Robert E} and Steinberg, {Michael L} and David Elashoff and Horwitz, {Eric M} and Tendulkar, {Rahul D} and Kishan, {Amar U}",
note = "Copyright {\textcopyright} 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2021",
month = aug,
doi = "10.1016/j.eururo.2021.04.035",
language = "English",
volume = "80",
pages = "142--146",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer

AU - Philipson, Rebecca G

AU - Romero, Tahmineh

AU - Wong, Jessica K

AU - Stish, Bradley J

AU - Dess, Robert T

AU - Spratt, Daniel E

AU - Pilar, Avinash

AU - Reddy, Chandana

AU - Wedde, Trude B

AU - Lilleby, Wolfgang A

AU - Fiano, Ryan

AU - Merrick, Gregory S

AU - Stock, Richard G

AU - Demanes, D Jeffrey

AU - Moran, Brian J

AU - Braccioforte, Michelle

AU - Tran, Phuoc T

AU - Martin, Santiago

AU - Martinez-Monge, Rafael

AU - Krauss, Daniel J

AU - Abu-Isa, Eyad I

AU - Valle, Luca

AU - Chong, Natalie

AU - Pisansky, Thomas M

AU - Choo, C Richard

AU - Song, Daniel Y

AU - Greco, Stephen

AU - Deville, Curtiland

AU - McNutt, Todd

AU - DeWeese, Theodore L

AU - Ross, Ashley E

AU - Ciezki, Jay P

AU - Tilki, Derya

AU - Karnes, R Jeffrey

AU - Klein, Eric A

AU - Tosoian, Jeffrey J

AU - Boutros, Paul C

AU - Nickols, Nicholas G

AU - Bhat, Prashant

AU - Shabsovich, David

AU - Juarez, Jesus E

AU - Kupelian, Patrick A

AU - Rettig, Matthew B

AU - Berlin, Alejandro

AU - Tward, Jonathan D

AU - Davis, Brian J

AU - Reiter, Robert E

AU - Steinberg, Michael L

AU - Elashoff, David

AU - Horwitz, Eric M

AU - Tendulkar, Rahul D

AU - Kishan, Amar U

N1 - Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2021/8

Y1 - 2021/8

N2 - The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously received either external beam radiation therapy (EBRT, n = 654, 67%) or EBRT + brachytherapy (EBRT + BT, n = 324, 33%) across 15 institutions from 1997 to 2015. In men who did not die, median follow-up after treatment was 8.9 yr and median follow-up after biochemical recurrence (BCR) was 3.7 yr. Local and systemic therapy salvage, respectively, were delivered to 21 and 390 men after EBRT, and eight and 103 men after EBRT + BT. Overall, 435 men developed DM, and 248 were detected within 1 yr of BCR. Measured from time of recurrence, 5-yr DM rates were 50% and 34% after EBRT and EBRT + BT, respectively. Measured from BCR, 5-yr PCSM rates were 27% and 29%, respectively. Interval to BCR was independently associated with DM (p < 0.001) and PCSM (p < 0.001). These data suggest that radiorecurrent HRPCa has an aggressive natural history and that DM is clinically evident early after BCR. These findings underscore the importance of further investigations into upfront risk assessment and prompt systemic evaluation upon recurrence in HRPCa. PATIENT SUMMARY: High-risk prostate cancer that recurs after radiation therapy is an aggressive disease entity and spreads to other parts of the body (metastases). Some 60% of metastases occur within 1 yr. Approximately 30% of these patients die from their prostate cancer.

AB - The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously received either external beam radiation therapy (EBRT, n = 654, 67%) or EBRT + brachytherapy (EBRT + BT, n = 324, 33%) across 15 institutions from 1997 to 2015. In men who did not die, median follow-up after treatment was 8.9 yr and median follow-up after biochemical recurrence (BCR) was 3.7 yr. Local and systemic therapy salvage, respectively, were delivered to 21 and 390 men after EBRT, and eight and 103 men after EBRT + BT. Overall, 435 men developed DM, and 248 were detected within 1 yr of BCR. Measured from time of recurrence, 5-yr DM rates were 50% and 34% after EBRT and EBRT + BT, respectively. Measured from BCR, 5-yr PCSM rates were 27% and 29%, respectively. Interval to BCR was independently associated with DM (p < 0.001) and PCSM (p < 0.001). These data suggest that radiorecurrent HRPCa has an aggressive natural history and that DM is clinically evident early after BCR. These findings underscore the importance of further investigations into upfront risk assessment and prompt systemic evaluation upon recurrence in HRPCa. PATIENT SUMMARY: High-risk prostate cancer that recurs after radiation therapy is an aggressive disease entity and spreads to other parts of the body (metastases). Some 60% of metastases occur within 1 yr. Approximately 30% of these patients die from their prostate cancer.

U2 - 10.1016/j.eururo.2021.04.035

DO - 10.1016/j.eururo.2021.04.035

M3 - Other (editorial matter etc.)

C2 - 33985797

VL - 80

SP - 142

EP - 146

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 2

ER -